39 results
Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial

Thumbnail

D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study

Thumbnail

D2.504 - Novel food supplement containing a combination of bioactive compounds in pediatric cow’s milk protein allergy: results from a randomized, placebo-controlled trial

Thumbnail

D3.140 - Transcriptomic profiling reveals distinct gene signatures and immune pathways in inhaled corticosteroid (ICS)-sensitive and resistant House Dust Mite (HDM)-induced asthma mouse models

Thumbnail

D3.141 - Serum levels of IL-10 and IFN-GAMMA in adolescents diagnosed with asthma in clinical remission without treatment

Thumbnail

D3.142 - Adherence to Inhaled Corticosteroid Therapy in Patients with Severe Asthma at a Danish Tertiary Care Centre

Thumbnail

D3.143 - Immunomodulatory role of vitamin D in severe asthma: a potential biomarker of treatment response

Thumbnail

D3.144 - Did allergic status change the quality of life in controlled severe asthma patients with triple therapy?

Thumbnail

D3.145 - Comparative particle size and distribution from fixed dose triple dry powder inhalers

Thumbnail

D3.146 - Attitudes and Knowledge Levels Regarding Physical Activity in Children with Asthma and Their Parents: A Comparison with Healthy Controls

Thumbnail

D3.147 - A Survey of Approaches to Inhaled Therapy Management in Patients with Severe Asthma Treated with Biologics: Practices Among REIMAGINE Study Sites

Thumbnail

D3.148 - ANCA-Negative Systemic Vasculitis Developing Despite Anti-IL-5R Therapy and High Dose of Glucocorticosteroids: A Diagnostic and Therapeutic Challenge